Olanzapine/samidorphan
Olanzapine/samidorphan (developmental code name ALKS-3831) is a combination of the atypical antipsychotic olanzapine and the opioid modulator samidorphan which is under development by Alkermes, Plc. for the treatment of schizophrenia and bipolar mania.[1][2][3] As of June 2017, it is in phase III clinical trials for this indication.[1]
| Combination of | |
|---|---|
| Olanzapine | Atypical antipsychotic |
| Samidorphan | Opioid modulator |
| Clinical data | |
| Other names | ALKS-3831 |
| Legal status | |
| Legal status | |
References
- "Olanzapine/samidorphan - Alkermes plc - AdisInsight".
- Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C (2016). "Improving Current Treatments for Schizophrenia". Drug Dev. Res. 77 (7): 357–367. doi:10.1002/ddr.21337. PMID 27633376.
- Fellner C (2017). "New Schizophrenia Treatments Address Unmet Clinical Needs". P T. 42 (2): 130–134. PMC 5265239. PMID 28163559.
External links
| Typical |
|
|---|---|
| Disputed | |
| Atypical |
|
| Others | |
| |
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.